PMS21 MIXED TREATMENT COMPARISONS- AN EVIDENCE-BASED BUDGET IMPACT MODEL OF RITUXIMAB (MABTHERA) AFTER FAILURE OF ONE OR MORE TNF INHIBITOR THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)75161-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)75161-5/fulltext
Title :
PMS21 MIXED TREATMENT COMPARISONS- AN EVIDENCE-BASED BUDGET IMPACT MODEL OF RITUXIMAB (MABTHERA) AFTER FAILURE OF ONE OR MORE TNF INHIBITOR THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)75161-5&doi=10.1016/S1098-3015(10)75161-5
First page :
Section Title :
Open access? :
No
Section Order :
1087